HC Wainwright Has Negative Outlook for VRDN Q1 Earnings

Key Points

• HC Wainwright cut its Q1 2026 EPS estimate for Viridian to ($1.16) from ($1.11) and lowered FY2026 to ($4.75) while maintaining a "Buy" rating and a $22 price target.
• Viridian last reported EPS of ($1.08) and revenue of $0.13M, missing estimates and showing a deeply negative net margin, highlighting near-term financial weakness.
• Despite a positive Phase 3 REVEAL‑1 topline for elegrobart, the stock plunged over 30% amid mixed sentiment and analyst target cuts—analyst consensus remains a "Moderate Buy" with a $39.21 target but views are diverging.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities researchers at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Viridian Therapeutics in a note issued to investors on Monday, March 30th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($1.16) for the quarter, down from their previous estimate of ($1.11). HC Wainwright has a "Buy" rating and a $22.00 price objective on the stock. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics' Q2 2026 earnings at ($1.22) EPS, Q4 2026 earnings at ($1.17) EPS and FY2026 earnings at ($4.75) EPS.

Several other research analysts have also recently issued reports on the stock. UBS Group assumed coverage on shares of Viridian Therapeutics in a report on Wednesday, January 7th. They set a "buy" rating and a $50.00 price target for the company. Royal Bank Of Canada lowered their price objective on Viridian Therapeutics from $45.00 to $42.00 and set an "outperform" rating on the stock in a report on Friday, February 27th. Truist Financial cut their target price on Viridian Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday, January 8th. Wedbush reduced their price target on Viridian Therapeutics from $44.00 to $37.00 and set an "outperform" rating for the company in a report on Tuesday. Finally, Wall Street Zen downgraded Viridian Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $39.21.

Viridian Therapeutics Stock Up 5.6%

VRDN stock opened at $19.56 on Wednesday. The stock has a market capitalization of $2.00 billion, a PE ratio of -5.95 and a beta of 1.00. The company has a fifty day moving average of $29.16 and a 200-day moving average of $27.89. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.65 and a current ratio of 12.65. Viridian Therapeutics has a one year low of $9.90 and a one year high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.18). The business had revenue of $0.13 million during the quarter, compared to analysts' expectations of $15.75 million. Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%.

Hedge Funds Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of VRDN. Simplify Asset Management Inc. purchased a new stake in Viridian Therapeutics during the 3rd quarter worth about $1,079,000. Hudson Bay Capital Management LP lifted its holdings in Viridian Therapeutics by 46.6% in the 3rd quarter. Hudson Bay Capital Management LP now owns 175,251 shares of the company's stock valued at $3,782,000 after purchasing an additional 55,689 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in Viridian Therapeutics by 135.6% in the 3rd quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company's stock valued at $25,922,000 after purchasing an additional 691,267 shares in the last quarter. Propel Bio Management LLC acquired a new stake in shares of Viridian Therapeutics during the 3rd quarter worth about $1,942,000. Finally, Y Intercept Hong Kong Ltd grew its holdings in shares of Viridian Therapeutics by 430.3% during the third quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company's stock worth $1,394,000 after buying an additional 52,414 shares in the last quarter.

Trending Headlines about Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 hit its primary endpoint: elegrobart produced statistically significant proptosis responder rates (Q4W 54%, Q8W 63% vs placebo 18%) — an important clinical validation that supports a potential approval path. Business Wire release
• Positive Sentiment: Multiple outlets reported the positive topline data (press coverage that confirms the readout and its details may help downstream regulatory and partnering discussions). Las Vegas Sun article
• Positive Sentiment: Some sell‑side firms remain constructive despite cuts — Goldman Sachs cut its target to $36 but kept a "buy" rating, Wedbush cut to $37 and kept "outperform", and Needham trimmed to $32 while retaining "buy" — these keep a material upside narrative for investors who focus on longer‑term commercial potential. Benzinga
• Neutral Sentiment: Market commentary and audio/newscasts are covering the swing (podcast coverage and “stocks to watch” lists) — reflects heightened attention but does not add new clinical or financial data. Bloomberg podcast
• Neutral Sentiment: News aggregators and analysts explain the paradox: the trial met its primary endpoint but market expectations for effect size, secondary endpoints, safety, dosing, or commercial assumptions may not have been met — this discussion is driving intraday volatility. Seeking Alpha
• Negative Sentiment: Several analysts trimmed price targets and/or lowered ratings: Wells Fargo cut target to $20 and moved to "equal weight", HC Wainwright cut to $22 (still "buy") — these downward revisions compress near‑term upside and signal more conservative commercial or launch assumptions. Benzinga
• Negative Sentiment: Despite positive topline data, the stock plunged (>30% in earlier trading) on investor disappointment and profit‑taking; coverage highlighting the selloff and "stock tumbles despite trial success" may amplify short‑term selling pressure. Investing.com

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.